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In an attempt to guide physicians asked by respiratory patients for advice on flight fitness, the
British Thoracic Society (BTS) have published guidelines on fitness to fly. The main potential
hazard is hypobaric hypoxia, and efforts have focused on the prediction of hypoxia in individ-
uals. The present study examines 10 years’ experience of hypoxic challenge (HC) of respiratory
patients to evaluate if the guidelines recommended by the BTS are appropriate.
One hundred and eighteen patients (67 female, mean age 65.6  11.4 (SD) years) were re-
ferred for assessment. Patients underwent HC using a 40% Venturi mask supplied with 100%
N2 which lowered the FiO2 to 15.1%. A further 13 patients on long-term oxygen therapy also
underwent HC whilst receiving supplemental oxygen.
In agreement with the BTS guidelines, all patients with a sea level SpO2 of over 95% main-
tained their SpO2 90% during HC. One third of patients with sea level SpO2 of 92e95%, but
no other risk factor (as defined by the guidelines) also desaturated below 90% during HC.
Thirty-two patients were assessed as fit to fly with supplemental oxygen.
Our results support the BTS guidelines for patients with a sea level SpO2 >95% but suggest
that some revision is required for patients with a sea level SpO2 of 92e95%. It was not possible
to predict from either initial SpO2 or spirometry which individuals were at risk of desaturation
below 90% during hypoxic challenge.
ª 2008 Elsevier Ltd. All rights reserved.(0)131 537 2575; fax: þ44
scot.nhs.uk (A.G. Robson).
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Air travel is rapidly increasing worldwide, therefore more
patients with respiratory disease will be wanting to fly. As
a consequence of this, patients with respiratory disease are
likely to ask their doctors ‘‘am I fit to fly?’’ At normal.
Hypoxic challenge in respiratory disease 1593cruising altitudes commercial aircraft are designed to
maintain a reduced cabin pressure which is equivalent to
an altitude of not greater than 2438 m. At this altitude the
pO2 is reduced to a value equivalent to an inspired fraction
of oxygen (FiO2) of 15.1% at sea level. The sigmoid shape of
the oxygen dissociation curve allows healthy individuals to
tolerate this reduction in pO2 without significant hypoxae-
mia, but passengers with respiratory disease may not be
able to increase their ventilation sufficiently to compensate
for the reduced pO2, leading to alveolar and tissue hypoxia.
To predict which patients with lung disease may be
hypoxic during flight a number of assessment protocols
have been developed.1e3 The British Thoracic Society (BTS)
and Aerospace Medical Association (AMA) have published
comprehensive guidelines4,5 to assist clinicians in advising
their patients. Both sets of guidelines recommend hypoxic
challenge as a means of identifying passengers at risk of sig-
nificant hypoxia during flight. The BTS Guidelines suggest
that hypoxic challenge is unnecessary for any patient with
an O2 saturation (SpO2) >95% and that those with an SpO2
<92% should fly with supplemental oxygen. For patients
with an SpO2 between 92% and 95% with additional risk fac-
tors, such as hypercapnia, restrictive disease or an FEV1
<50% predicted, the guidelines suggest a hypoxic chal-
lenge. Our laboratory has been performing hypoxic chal-
lenge to assess flight fitness since 1997, and the data
collected over the last ten years have been evaluated to
examine if the BTS criteria are valid.
Methods
Patients
One hundred and eighteen patients (67 female, mean age
65.6  11.4 (SD) years) were referred to the laboratory (al-
titude 30 m above sea level) for assessment of flight fitness.
Referrals came from hospital and primary care physicians,
primarily at the request of the patient. As this assessment
is one of the routine clinical assessments made by our lab-
oratory and we are reporting an audit of the outcome of
these assessments, we were advised that formal Ethics
Committee approval was not required. The patients were
classified into disease groups using only the information
included in the referral form or letter. Most patients
(63%) had a diagnosis of chronic obstructive pulmonary dis-
ease (COPD) (see Table 1 for a full breakdown of diagnosis).
Seventy-eight patients were ex-smokers, 18 were current
smokers and the remaining 22 non-smokers. Spirometric
data (FEV1 and VC) were compared with appropriate refer-
ence values.6 Only patients who were clinically stable, i.e.
no self-reported deterioration in their condition or who had
not been prescribed antibiotics or had any change in oral
steroid therapy within the previous 4 weeks, were consid-
ered for assessment.
Hypoxic challenge protocol and interpretation
Oxygen saturation was recorded continuously throughout
the assessment and the values noted at 30-s intervals
during a 5-min period of rest, breathing room air, using an
earlobe probe connected to a pulse oximeter (Model 3740;Ohmeda, Guilford, UK). Before measurements of SpO2 were
made the patient’s earlobe was prepared by rubbing with
a topical vasodilator cream (Ralgex, Seton Medical Group,
Oldham, UK).
All patients with a sea level SpO2 90% underwent a
20-min hypoxic challenge (HC). The decision to perform
hypoxic challenge in all these subjects, not just those
with a starting SpO2 of 95% or under predates the BTS guide-
lines and provides the opportunity for a clinical validation
of the BTS 95% cut-off value. The method of Vohra and
Klocke7 was used, which employs a 40% Venturi mask, sup-
plied with 10 L/min 100% N2 to lower the patient’s FiO2 to
0.15. The accuracy of the FiO2 was checked using an oxygen
sensor sampling directly from just outside the mouth.
Inspired oxygen was 0.15 in 15 healthy subjects and
6 COPD patients with an intersubject standard deviation
of 0.02.
The results of hypoxic challenge were interpreted
according to a locally derived algorithm (which predates
the BTS guidelines) described elsewhere8 and shown in
Fig. 1. If SpO2 remained 90% during HC, patients were
classed as fit to fly without supplemental O2 (Group A). If
SpO2 fell below 90% during HC, patients were given supple-
mental oxygen (2 L/min via nasal cannulae placed under
the Venturi mask) and the HC repeated once SpO2 had sta-
bilised. If SpO2 remained 90%, patients were classified as
fit to fly with supplemental O2 (Group B). If the SpO2 still
fell below 90%, the HC would be stopped, the flow of sup-
plemental O2 increased to 4 L/min and a third HC per-
formed. If the SpO2 still remained <90% patients were
classified as likely to be hypoxic even with supplemental
oxygen, and they were advised against air travel (Group C).
An additional 13 patients were referred who were
receiving long-term oxygen therapy (LTOT). In these,
hypoxic challenge began with them receiving 2 L/min sup-
plemental O2 (by nasal cannulae placed under the Venturi
mask) throughout the assessment. If their SpO2 remained
90% during HC they were classified in Group B. If SpO2
fell below 90% on HC the flow of O2 was increased to 4 L/
min and HC was repeated. If SpO2 remained 90% they
were classified as fit to fly with increased supplemental
O2 (group B). If SpO2 still fell to <90% they were advised
against air travel (Group C).
Statistical analyses were carried out using a commercial
statistical package (Sigmastat, SPSS, UK). To examine which
variables might predict desaturation, scatter plots of FEV1
(both absolute values and % predicted) against percentage
desaturation on HC were inspected. All data were sub-
jected to the KolmogoroveSmirnov normality test. As
data were not normally distributed, Spearman rank correla-
tions were used. A probability value of <0.05 was consid-
ered statistically significant.
Results
Hypoxic challenge
Ninety patients (76% of the study group) were able to
maintain SpO2 90% during HC (Group A). Twenty-seven
patients (23% of the study group) required supplemental ox-
ygen (2 L/min) to maintain SpO2 90% during HC (Group B).
Table 1 Patient details, broken down by the primary diagnosis recorded on the request form
Primary diagnosis No. of
patients
assessed
Age FEV1 VC FEV1/VC
ratio
% predicted
FEV1
% predicted
VCYears Litres Litres
COPD 74 68.6  8.5 1.14  0.55 2.50  0.85 46.6  15.8 47  21 77  17
Interstitial lung disease 18 67.3  9.5 1.48  0.76 2.11  0.82 69.0  19.1 60  27 68  21
CF or bronchiectasis 8 55.0  18.3 1.86  0.68 2.56  0.83 74.0  15.1 67  28 70  23
Asthma 5 52.2  16.6 1.44  0.63 2.37  0.32 59.4  24.0 58  30 79  20
Obstructive sleep apnoea 3 57.0  12.0 1.67  0.37 2.70  0.96 65.0  20.0 63  21 75  19
Previous pneumonia 3 62.5  9.0 1.83  1.44 2.97  1.80 58.7  16.6 63  20 83  16
Neuromuscular disease 2 51.2  2.0 0.88  0.18 1.05  0.35 85.3  11.9 45  15 44  23
Pulmonary vascular disease 2 60.3  15.9 2.14  0.66 3.03  1.24 72.2  7.8 68  9 78  12
Thoracic neoplasm 2 70.7  4.4 1.40  0.14 2.55  1.06 61.4  31.1 43  3 61  26
Previous ARDS 1 36 1.90 2.10 90 45 40
Mean  1 SD values for absolute values and % predicted FEV1 and VC are shown.
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ling (Group C).
Of the additional 13 patients on LTOT, 8 maintained SpO2
90% on HC while receiving supplemental O2 at 2 L/min and
4 patients required increased supplemental O2 (4 L/min) to
maintain SpO2 90%. One patient was unable to maintain
their SpO2 >90% even with the addition of 4 L/min supple-
mental O2.
With reference to the BTS guidelines, results confirm
that all patients with a sea level SpO2 >95% did not desatu-
rate to <90% on hypoxic challenge (Fig. 2). The BTS guide-
lines suggest that patients with a sea level SpO2 between
92% and 95% only require hypoxic challenge if they also
have additional risk factors. In the present study 59
patients not on LTOT had a sea level SpO2 between 92%
and 95%. Thirty-eight (64%) of these had additional riskO2 saturation breath
SpO2 >90%
SpO2 ≥90%
SpO2 ≥ 90%
SpO2 <90%
Hypoxic challenge
Hypoxic
suppleme
Fit to fly
Fit to fly with
supplemental oxygen
Figure 1 Hypoxic challengefactors as defined by the BTS (31 with FEV1 <50% predicted
value and 7 with restrictive and/or interstitial disease).
Thirty-four patients (of the 59 with a sea level SpO2
between 92% and 95%) were fit to fly without oxygen (Group
A) and 25 required supplemental O2 (Group B). Seven
patients categorised as requiring supplemental oxygen dur-
ing flight had no additional BTS-defined risk factors.
Relationship between sea level SpO2, spirometry
and response to hypoxic challenge
Fig. 3 shows the absolute desaturation observed during hyp-
oxic challenge plotted against level of sea level oxygen sat-
uration for all patients not on LTOT. As expected from the
oxygen dissociation curve, Figure 3 shows a weak, but sta-
tistically significant trend towards greater desaturation oning room air
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Figure 2 Percentage of all patients not on LTOT undergoing
hypoxic challenge who were able to maintain their O2 satura-
tion above 90%, subdivided by pre-test sea level O2 saturation.
Figure 4 Relationship between FEV1 (expressed as a percent-
age of predicted value) and absolute desaturation on hypoxic
challenge for all patients not on LTOT.
Table 2 Results of hypoxic challenge for patients not on
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tion, but with marked variability (RZ 0.312, P < 0.001).
There was no correlation between disease severity as mea-
sured by FEV1 (% predicted) and either initial SpO2 or the
lowest SpO2 recorded during hypoxic challenge, either in
the patient group as a whole (RZ 0.116 and 0.123 respec-
tively) or in the subset with COPD (RZ 0.127 and 0.070 re-
spectively). Similarly, there was no correlation between %
predicted FEV1 and the degree of desaturation on HC
(RZ 0.149, PZ 0.108) (Fig. 4).
Influence of diagnostic category on response to
hypoxic challenge
Table 2 shows the results for each diagnostic category. In
this data set, there was no significant effect (z-test) of
diagnostic category on the response to hypoxic challenge.Figure 3 Correlation between pre-test sea level O2 satura-
tion and absolute desaturation on hypoxic challenge for all
patients not on LTOT.Predictability of desaturation in individuals from
spirometry or sea level saturation
Table 3 shows examples of how individual patients with the
same diagnosis, spirometry and sea level saturation can
have markedly different responses to hypoxic challenge.
Even in the limited numbers studied, it is clear that desatu-
ration during HC in individuals cannot be predicted reliably
from either FEV1 or sea level SpO2. The patient with the
lowest FEV1 in the study showed no clinically significant
desaturation on hypoxic challenge.
Discussion
This paper reports our experience of assessing 131 pa-
tients (including 13 on LTOT) for their fitness to fly using
hypoxic challenge and a locally derived interpretation
algorithm. Patients with a range of chronic respiratory
diseases, with a range of severities have been assessed.LTOT, broken down by diagnostic category
Primary
diagnosis
Number of
patients
assessed
Fit
to fly
Fit to fly with
supplemental
oxygen
Unfit
to fly
COPD 74 73 26 1
Interstitial lung
disease
18 71 29 0
CF or
bronchiectasis
8 88 12 0
Asthma 5 100 0 0
Obstructive sleep
apnoea
3 100 0 0
Previous
pneumonia
3 100 0 0
Neuromuscular
disease
2 50 50 0
Pulmonary
vascular disease
2 50 50 0
Thoracic neoplasm 2 100 0 0
Previous ARDS 1 100 0 0
Table 3 Predictability of desaturation in individual
patients from spirometry or sea level saturation
Gender Age % Predicted
FEV1
Sea
level
SpO2
Lowest
SpO2
Matching FEV1 M 65 27 92 82
M 70 26 97 94
Matching sea
level SpO2
M 73 58 94 85
F 64 31 94 91
Lowest FEV1 in
study group
M 54 13 98 93
The first two rows of the table show pairs of patients with
COPD, matched either for FEV1% predicted or sea level SpO2.
Desaturation during hypoxic challenge is unpredictable in indi-
viduals. Even combining these predictors is unreliable; in the
two patients with matching sea level SpO2 it was the patient
with the higher FEV1 who desaturated significantly. The final
row shows hypoxic challenge results for a patient with COPD
who has the lowest % predicted FEV1 in the study but yet did
not desaturate below 93%.
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minimum value for initial SpO2 at which SpO2 can be
maintained at or above 90% during hypoxic challenge
equivalent to cabin conditions. The results suggest (in
support of the BTS guidelines) that patients with a starting
SpO2 breathing air of over 95% should be able to maintain
O2 saturation at or above 90% during air travel. For the
group of patients not on LTOT with a sea level SpO2
between 92% and 95%, however, we found that 42% of pa-
tients (25 out of 59) did desaturate below 90% on hypoxic
challenge, and that 28% (7 out of 25) of those patients
showing significant desaturation did not have any of the
additional risk factors as suggested by the BTS. This
suggests that hypoxic challenge may be of value to all
patients in this group, not just those with the predefined
risk factors suggested by the BTS.
For the population not requiring LTOT referred to in the
present study, these results indicate that 28 patients (23%
of those referred for evaluation) were at risk of desatura-
tion below 90% during air travel. In 97% of these cases the
desaturation could be prevented by supplemental O2 at
a flow of 2 L/min. Only 1 patient out of the study popula-
tion of 118 not on LTOT (0.8%) was considered to be too
hypoxic to fly, i.e. their SpO2 remained <90%, despite sup-
plemental oxygen at 4 L/min.
Is hypoxic challenge necessary, or can hypoxia be
predicted from other tests? Table 3 illustrates pairs of
patients with COPD who have identical impairment of
FEV1 or identical sea level O2 saturation but who respond
very differently to hypoxic challenge.
A number of authors have used measurements of ground
level PaO2 in an attempt to predict in-flight PaO2 and thus
identify patients at risk of significant hypoxia. Gong
et al.1 found a good agreement between the two variables
in patients with COPD and published a prediction equation
allowing an estimate of in-flight PaO2 to be made from
ground level values. Dillard et al.3 found that the addition
of ground level FEV1 improved the ability to predictaccurately in-flight PaO2 in COPD patients. Christensen
et al.10 found that sea level pO2 is an unreliable predictor
of individual response to hypoxic challenge in patients
with COPD. Seccombe et al.11 also found that resting, sea
level arterial blood gas analysis was not a good predictor
of the response to simulated cabin altitude in patients
with either COPD or interstitial lung disease. While some
of these papers report statistically significant correlations
in small groups of patients between sea level measure-
ments and measurements during hypoxic challenge, what
matters to patients is their individual result. In all the pub-
lished papers, and in the present much larger data set
(Fig. 2 and Table 3), the scatter of individual results within
the group precludes reliable prediction in individuals even
when group correlations are significant. This limits the
utility of predicted equations such as those described by
Gong et al. and Dillard et al. when advising individual
patients.
The present study could be criticised for including
patients with a wide variety of respiratory conditions of
varying severity; however, this reflects the actual demand
for information received by a teaching hospital laboratory.
Table 2 indicates that no particular diagnostic group
appeared to be more at risk of hypoxia than others, within
the constraints of the numbers studied.
Does desaturation worsen with prolonged flight? Most
hypoxic challenge protocols are of 20e30 min duration. It is
assumed that this is long enough for any physiological
changes to have taken place. Akerø et al.12 have investigated
hypoxia in a group of patients with COPD during a 6 h flight
and found that there was an initial fall in PaO2 once the flight
had reached cruising altitude which was maintained
throughout the flight. Fischer et al.13 have studied hypoxia
in patients with cystic fibrosis at low altitude (530 m) and af-
ter 7 h at high altitude (2650 m). Patients were hypoxic at
altitude but there was no trend to worsening with time and
few reported any additional symptoms. Once again there
were no robust individual predictors of hypoxia.
Importantly, does it matter if patients desaturate during
flight? In designing the local protocol, which pre-dates the
publication of the BTS guidelines, a clinical decision was
made that desaturation at rest below 90% was significant
hypoxia. The likelihood of additional hypoxia if these
resting patients moved during flight led to a precautionary
approach to patients referred with a resting SpO2 below
90%. The link between hypoxia and actual clinical risk
remains poorly understood; however, recent work has high-
lighted mechanisms whereby hypoxia predisposes to a vari-
ety of clinical risks. Hypoxia of the magnitude encountered
in flight appears to be thrombogenic in those with other
risk factors,14 but not in healthy young subjects with no
additional risk factors.15 Pulmonary hypertension is
a well-recognised consequence of hypoxia, and some of
the cellular mechanisms are now being elucidated.16
Chronic hypoxia (even mild levels) has detectable cognitive
effects on children17 and acute hypoxia at altitude affects
the mental functioning of an adult aircrew,18 even at alti-
tudes below 10,000 feet.19 Thus it is not unreasonable to
use hypoxia as a surrogate for clinical risk even though
the individual risk of adverse effects from hypoxia remains
uncertain. Flight diversions for respiratory symptoms are
uncommon;20,21 however, it seems likely that those with
Hypoxic challenge in respiratory disease 1597marked desaturation (despite supplemental oxygen) will
include those at most clinical risk.
In conclusion, the majority of patients referred to
a routine laboratory for assessment of their fitness to fly
do not develop significant hypoxia during exposure to a low
oxygen environment simulating flight. Approximately one
quarter of these patients will require supplemental oxygen
to prevent desaturation below 90%, but the individual’s
need for supplemental oxygen cannot be predicted from
either spirometry or sea level oxygen saturation, with the
exception that hypoxic challenge appears unnecessary in
patients with a sea level SpO2 of over 95%.
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